A bell curve, not a slope

A 2.6-fold jump in brain delivery between 2.3 nm and 15 nm particles, followed by a 2.5-fold drop at 45 nm, defines a bell-shaped transport curve that contradicts the long-held "smaller is better" rule for focused-ultrasound (FUS) drug delivery across the blood–brain barrier.

The University of Virginia team led by senior author Richard J Price and first author Matthew Hoch published these findings in Radiology (DOI: 10.1148/radiol.251005). They tested four particles spanning a 20-fold size range: a 2.3 nm gadolinium contrast agent (MultiHance) and iron oxide nanoparticles (IONPs) at 15, 23, and 45 nm — the latter three sized to mirror immunotherapy and gene-therapy candidates.

What did the new MRI method unlock?

Standard MRI hits walls when sizing up neurotherapeutics. T1-mapping tops out at small commercial contrast agents. T2 iron mapping drags on with long scan times for 3D imaging and loses sensitivity at low concentrations. Fluorescence is semi-quantitative. PET gives up spatial resolution.

The UVA group solved this with quantitative susceptibility mapping (QSM), an MRI post-processing technique that exploits magnetic field distortions caused by iron-loaded nanoparticles. QSM turned the scanner into a nanoparticle detector sensitive enough to quantify tissue concentrations down to fractions of a percent of the injected dose.

What did healthy-brain mice show?

Delivery climbed from the 2.3 nm MultiHance baseline through the 15 nm IONP, then plateaued at 23 nm. At 45 nm, delivery collapsed to roughly the same level as the smallest agent. The 15–23 nm sweet spot reflects two competing forces:

• Smaller particles squeeze through the disrupted barrier more easily
• Larger particles circulate longer, gaining more chances to cross

Researchers attribute the bell shape to that trade-off between permeability and circulation time.

How did tumour-bearing mice respond?

Glioma-carrying mice present an added barrier — the blood–tumour barrier, marked by high tissue pressures and inconsistent flow. The team expected delivery to drop relative to healthy brain. Instead, FUS boosted transport of both small and large agents into tumours at levels matching healthy tissue.

"The outcome is exciting because it means that focused ultrasound delivery performance is not expected to diminish in brain tumours," Price said in a press statement. "In fact, it may even be enhanced for some types of therapeutics."

What does this change for R&D portfolios?

FUS-mediated barrier opening is already in clinical trials for Alzheimer's disease and glioblastoma. The UVA data give drug developers two actionable signals. Particle engineering should target the 15–23 nm band rather than chasing the smallest possible payload. And QSM provides a quantitative readout that any lab with iron-based formulations and a 3D MRI sequence can adopt to verify delivery.

The work also repositions a physics tool — QSM, originally used for haemorrhage, iron-deposition and calcification imaging — as a biology answer. For portfolio planning, the bell curve sets a clear size-selection criterion for gene- and immunotherapy candidates aimed at the central nervous system.

What remains untested?

The study ran in mice using iron oxide nanoparticles as drug proxies, not therapeutic payloads. Sample sizes, exact tumour models, and human translation are still open. The next checkpoint will be the human trials already underway, where QSM-derived concentration maps could shape dose-escalation rules and particle-engineering decisions for glioblastoma and Alzheimer's programmes.